A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

NCT00818675 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Lead-In Ridaforolimus
DRUG: Comparator: Blinded Ridaforolimus
DRUG: Comparator: Blinded Placebo

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]